WO2009013614A3 - Marker gene - Google Patents
Marker gene Download PDFInfo
- Publication number
- WO2009013614A3 WO2009013614A3 PCT/IB2008/001957 IB2008001957W WO2009013614A3 WO 2009013614 A3 WO2009013614 A3 WO 2009013614A3 IB 2008001957 W IB2008001957 W IB 2008001957W WO 2009013614 A3 WO2009013614 A3 WO 2009013614A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- bmi
- mrna
- protein
- cml
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A method of aiding in prognosing chronic myeloid leukemia (CML) by determining the level of BMI-1 mRNA or protein in a sample provided from a patient. A method of increasing the life expectancy of a patient in the chronic phase of chronic myeloid leukemia comprising administering a compound which is capable of reducing the expression or function of BMI-1 mRNA or protein in the patient. A method of aiding in assessing the suitability of a patient with CML to receive an allogeneic stem cell transplant, or such a transplant after enhanced prophylaxis for graft versus host disease, comprising determining the level of BMI-1 mRNA or protein in a sample provided from a patient. Associated methods of treating a patient, depending on the outcome of such assessment are provided
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0714573.3 | 2007-07-26 | ||
GB0714573A GB0714573D0 (en) | 2007-07-26 | 2007-07-26 | Marker gene |
US98745507P | 2007-11-13 | 2007-11-13 | |
US60/987,455 | 2007-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009013614A2 WO2009013614A2 (en) | 2009-01-29 |
WO2009013614A3 true WO2009013614A3 (en) | 2009-05-07 |
Family
ID=38512906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/001957 WO2009013614A2 (en) | 2007-07-26 | 2008-07-25 | Marker gene |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0714573D0 (en) |
WO (1) | WO2009013614A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009009672A1 (en) * | 2009-02-19 | 2010-09-02 | Johannes-Gutenberg-Universität Mainz | Regulatory nucleic acid of a human proteinase 3 variant |
ES2637853T3 (en) * | 2009-10-20 | 2017-10-17 | Diatech Holdings, Inc. | Proximity-mediated assays to detect oncogenic fusion proteins |
AU2013348009C1 (en) | 2012-11-21 | 2019-08-08 | Ptc Therapeutics, Inc. | Substituted reverse pyrimidine Bmi-1 inhibitors |
NZ748260A (en) * | 2013-08-30 | 2020-01-31 | Ptc Therapeutics Inc | Substituted pyrimidine bmi-1 inhibitors |
WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
KR101820572B1 (en) * | 2015-08-12 | 2018-01-19 | 가톨릭대학교 산학협력단 | Method for providing the information for chronic myeloid leukemia |
US10253371B2 (en) | 2016-08-29 | 2019-04-09 | National Guard Health Affairs | Method of treating leukemia based on gene expression of clock genes |
-
2007
- 2007-07-26 GB GB0714573A patent/GB0714573D0/en not_active Ceased
-
2008
- 2008-07-25 WO PCT/IB2008/001957 patent/WO2009013614A2/en active Application Filing
Non-Patent Citations (6)
Title |
---|
CHOWDHURY M ET AL: "Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia.", LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K MAY 2007, vol. 21, no. 5, May 2007 (2007-05-01), pages 1116 - 1122, XP002506316, ISSN: 0887-6924 * |
MENG XIU-XIANG ET AL: "Construction of antisense Bmi-1 expression plasmid and its inhibitory effect on K562 cells proliferation.", CHINESE MEDICAL JOURNAL 20 AUG 2005, vol. 118, no. 16, 20 August 2005 (2005-08-20), pages 1346 - 1350, XP002506314, ISSN: 0366-6999 * |
MERKEROVA MICHAELA ET AL: "Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, vol. 48, no. 4, 1 April 2007 (2007-04-01), pages 793 - 801, XP009109369, ISSN: 1042-8194 * |
MOHTY MOHAMAD ET AL: "The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.", BLOOD 1 JUL 2007, vol. 110, no. 1, 1 July 2007 (2007-07-01), pages 380 - 383, XP002506313, ISSN: 0006-4971 * |
YONG AGNES S M ET AL: "Hematopoietic stem cells and primitive progenitors express leukemia associated antigens that may be targets for graft-versus-leukemia effect or for vaccine-based immunotherapy in chronic myeloid leukemia.", BLOOD, vol. 108, no. 11, Part 1, November 2006 (2006-11-01), & 48TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ORLANDO, FL, USA; DECEMBER 09 -12, 2006, pages 602A - 603A, XP002506315, ISSN: 0006-4971 * |
YONG AGNES S M ET AL: "Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.", BLOOD 1 JAN 2006, vol. 107, no. 1, 1 January 2006 (2006-01-01), pages 205 - 212, XP002506317, ISSN: 0006-4971 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009013614A2 (en) | 2009-01-29 |
GB0714573D0 (en) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009013614A3 (en) | Marker gene | |
Arai et al. | Regulation of NCAPG by miR‐99a‐3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC | |
Fang et al. | Cancer stem cells and epithelial–mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches | |
Kasajima et al. | mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours | |
Sahay et al. | The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer | |
Xiao et al. | MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis | |
Grinat et al. | The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness | |
Ogawa et al. | Silencing of connexin 43 suppresses invasion, migration and lung metastasis of rat hepatocellular carcinoma cells | |
Liu et al. | LncRNA MNX1‐AS1 promotes the progression of cervical cancer through activating MAPK pathway | |
Zhu et al. | Elevated KIAA 0101 expression is a marker of recurrence in human gastric cancer | |
MX2009002936A (en) | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors. | |
Hu et al. | Long noncoding RNA HOXD-AS1 regulates proliferation of cervical cancer cells by activating Ras/ERK signaling pathway. | |
NZ593228A (en) | Gene expression markers (inhba) for colorectal cancer prognosis | |
Cai et al. | Sphingosine kinase 1: A novel independent prognosis biomarker in hepatocellular carcinoma | |
WO2007085497A3 (en) | Markers for the prediction of outcome of anthracycline treatment | |
Croset et al. | Tumour-derived miRNAs and bone metastasis | |
Xie et al. | miRNA-124 down-regulates SOX8 expression and suppresses cell proliferation in non-small cell lung cancer | |
Zhao et al. | LncRNA ZEB1‐AS1 down‐regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma | |
Dahan et al. | Induction of angiotensin-converting enzyme after miR-143/145 deletion is critical for impaired smooth muscle contractility | |
He et al. | miR‐96 regulates migration and invasion of bladder cancer through epithelial‐mesenchymal transition in response to transforming growth factor‐β1 | |
WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
Li et al. | Retracted: MicroRNA‐373 promotes the development of endometrial cancer by targeting LATS2 and activating the Wnt/β‐Catenin pathway | |
WO2008115470A3 (en) | Hox-gene expression as a biomarker for igf-1r therapeutics | |
Zhao et al. | GOLPH3 promotes angiogenesis of lung adenocarcinoma by regulating the Wnt/β-catenin signaling pathway | |
Xuan et al. | MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08788937 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08788937 Country of ref document: EP Kind code of ref document: A2 |